Magnolia officinalis: botanical characteristics, pharmacological properties and current evidence from preclinical studies

Magnolia officinalis, commonly known as "Houpo" in traditional Chinese medicine, has a documented history of use spanning over 2,500 years. It remains a widely traded botanical product in both Chinese and Japanese herbal pharmacopeias, where its bark has been traditionally employed in the management of various conditions, including anxiety, depression, gastrointestinal and respiratory disorders, stroke, and musculoskeletal pain. However, while its historical relevance in traditional medicine is well-established, the scientific basis for many of its purported benefits remains incompletely validated. This review critically examines the current scientific literature concerning the phytochemical composition, pharmacological properties, therapeutic applications, and safety profile of M. officinalis bark, using databases such as PubMed, ScienceDirect, HerbMed, and Google Scholar. Particular focus is placed on its two principal neolignan constituents, magnolol and honokiol, which have attracted considerable attention due to their reported antioxidant, anti-inflammatory, neuroprotective, anticancer, and anxiolytic effects. Although a growing body of in vitro and in vivo evidence supports the biological activity of these compounds, notable limitations persist, most notably, a lack of high-quality clinical trials, standardization in extract preparation, and a comprehensive understanding of their pharmacokinetics and drug interaction potential. While preliminary data suggest promising therapeutic avenues, the current body of evidence does not yet support widespread clinical translation. Thus, continued rigorous investigation, including mechanistic studies and well-designed human trials, is essential before M. officinalis and its active constituents can be considered viable candidates for modern pharmacotherapeutic development.

1. Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B 2017;18:194-214.

2. CPC (Chinese Pharmacopoeia Commission) Pharmacopoeia of the People’s Republic of China (English Edition) Beijing, China: China Medical Science Press; 2010.

3. Iwasaki K, Wang Q, Seki H, et al. The effects of the traditional Chinese medicine Banxia Houpo Tang on the swallowing reflex in Parkinson’s disease. Phytomedicine 2000;7:259–63.

4. Li N, Liang Y, Zhang L, et al. Neolignans in Magnolia officinalis as natural anti-Alzheimer's disease agents: A systematic review. Ageing Res Rev 2024;99:102398.

5. Banik K, Ranaware AM, Deshpande V, et al. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res 2019;144:192–209.

6. Xiang H, Zhang Q, Qi B, et al. Chinese herbal medicines attenuate acute pancreatitis: Pharmacological activities and mechanisms. Front Pharmacol 2017;8:216.

7. Talarek S, Listos J, Barreca D, et al. Neuroprotective effects of honokiol: From chemistry to medicine. Biofactors 2017;43:760–9.

8. Niu L, Wang J, Shen F, et al. Magnolol and honokiol target TRPC4 to regulate extracellular calcium influx and relax intestinal smooth muscle. J Ethnopharmacol 2022;290:115105.

9. Tan Y, Yu H, Sun S, et al. Honokiol exerts protective effects on neural myelin sheaths after compressed spinal cord injury by inhibiting oligodendrocyte apoptosis through regulation of ER-mitochondrial interactions. J Spinal Cord Med 2022;45:595–604.

10. Wang H, Liao Z, Sun X, et al. Intravenous administration of honokiol provides neuroprotection and improves functional recovery after traumatic brain injury through cell cycle inhibition. Neuropharmacology 2014;86:9–21.

11. Rickert U, Cossais F, Heimke M, et al. Anti-inflammatory properties of honokiol in activated primary microglia and astrocytes. J Neuroimmunol 2018;323:78–86.

12. Hsiao YP, Chen HT, Liang YC, et al. Development of nanosome-encapsulated honokiol for intravenous therapy against experimental autoimmune encephalomyelitis. Int J Nanomedicine 2020;15:17–29.

13. Tao W, Hu Y, Chen Z, et al. Magnolol attenuates depressive-like behaviors by polarizing microglia towards the M2 phenotype through the regulation of Nrf2/HO-1/NLRP3 signaling pathway. Phytomedicine 2021;91:153692.

14. Yeh PS, Wang W, Chang YA, et al. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration. Cancer Lett 2016;370:66–77.

15. Kim GD, Oh J, Park HJ, et al. Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells. Int J Oncol 2013;43:600–10.

16. Suo N, Guo YE, He B, et al. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia 2019;67:1320–32.

17. Huang J, Yang J, Zou X, et al. Ginkgolide B promotes oligodendrocyte precursor cell differentiation and survival via Akt/CREB/Bcl-2 signaling pathway after white matter lesion. Exp Biol Med (Maywood) 2021;246:1198–209.

18. Zhang Z, Shu X, Cao Q, et al. The compound of Magnolia officinalis improves white matter lesions by promoting the maturation of oligodendrocytes in chronic cerebral ischemia patterns. Taurine Neurosci 2023;39:1497–511.

19. Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology 2012;62:2507-14.

20. Schifano F, Guarino V, Papanti DG, et al. Is there a potential for misuse for the compounds/metabolites of Magnolia officinalis? Hum Psychopharmacol 2017;32:e2605.

21. Borgonetti V, Governa P, Manetti F, et al. A Magnolia officinalis enriched with honokiol Rehder & E.H. Wilson bark extract has an anxiolytic activity with a neuroprotective effect through the modulation of the CB1 receptor. J Pharm Pharmacol 2021;73:1161–8.

22. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 2009;11:239–55.

23. Yang EJ, Lee JY, Park SH, et al. Neuroprotective effects of neolignans isolated from Magnoliae Cortex against glutamate-induced apoptotic stimuli in HT22 cells. Food Chem Toxicol 2013;56:304–12.

24. Woodbury A, Yu SP, Wei L, et al. Neuro-modulating effects of honokiol: a review. Front Neurol 2013;4:130.

25. Kuo NC, Huang SY, Yang CY, et al. Involvement of HO-1 and autophagy in the protective effect of magnolol in hepatic steatosis-induced NLRP3 inflammasome activation in vivo and in vitro. Antioxidants (Basel) 2020;9:1–19.

26. Sarrica A, Kirika N, Romeo M, et al. Safety and toxicology of magnolol and honokiol. Planta Med 2018;84:1151–64.

27. Zhu L, Ge G, Liu Y, et al. Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica 2012;42:1001–8.

28. Zhu L, Ge G, Zhang H, et al. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2012;40:529–38.

29. Koetter U, Barrett M, Lacher S, et al. Interactions of Magnolia and Ziziphus extracts with selected central nervous system receptors. J Ethnopharmacol 2009;124:421–25.

30. Zhang WW, Li Y, Wang XQ, et al. Effects of magnolol and honokiol derived from traditional Chinese herbal remedies on gastrointestinal movement. World J Gastroenterol 2005;11:4414–18.

31. Yin HQ, Kim YC, Chung YS, et al. Honokiol inverts alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicol Appl Pharmacol 2009;236:124–30.

32. Niu L, Hou Y, Jiang M, Bai G. The rich pharmacological activities of Magnolia officinalis and secondary effects based on significant intestinal contributions. J Ethnopharmacol 2021;281:114524.

33. Liu S, Yang D, Li W, et al. Magnolia officinalis alcohol extract relieves intestinal lesions induced by Polygala tenuifolia by regulating the PI3K/AKT/NF-κB signaling pathway and intestinal flora. Drug Dev Res. 2024;18:1695–710.

34. Huang B, Gui M, An H, et al. Babao Dan alleviates gut immune and microbiota disorders while impacting the TLR4/MyD88/NF-κB pathway to attenuate 5-fluorouracil-induced intestinal injury. Biomed Pharmacother 2023;166:115387.

35. Feng W, Liu J, Huang L, et al. Gut microbiota as a target to limit toxic effects of traditional Chinese medicine: implications for therapy. Biomed Pharmacother 2021;133:111047.

36. Kim H, Lim CY, Chung MS. Magnolia officinalis and its honokiol and magnolol constituents inhibit human norovirus surrogates. Foodborne Pathog Dis 2021;18:24–30.

37. Fontana RB, Mattioli L, Biotti G, et al. Magnolia officinalis L. bark extract and respiratory diseases: From traditional Chinese medicine to Western medicine through the target network. Phytother Res 2023;37:2915–38.

38. Yuan Y, Zhou X, Wang Y, et al. Cardiovascular modulating effects of magnolol and honokiol, two polyphenolic compounds from traditional Chinese medicine Magnolia officinalis. Curr Drug Targets 2020;21:559–72.

39. Chen L, Li W, Qi D, et al. Honokiol protects pulmonary microvascular endothelial barrier against lipopolysaccharide-induced ARDS partially via the Sirt3/AMPK signaling axis. Life Sci 2018;210:86–95

40. Liang X, Xing W, He J, et al. Magnolol administration in normotensive young spontaneously hypertensive rats postpones the development of hypertension: role of increased PPARγ, reduced TRB3 and resultant alleviative vascular insulin resistance. PLoS One 2015;10:e0120366.

41. Olas B. The cardioprotective effect of Magnolia officinalis and its major bioactive chemical constituents. Int J Mol Sci 2025;26:4380.

42. Zhao X, Li F, Sun W, Gao L, Kim KS, Kim KT, et al. Extracts to prevent diabetic complications induced by the Magnolia species: a brief review. Int J Mol Sci 2024;17:1629.

43. Atanasov AG, Wang JN, Gu SP, et al. Honokiol: A non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 2013;1830:4813–19.

44. Choi SS, Cha BY, Lee YS, et al. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci 2009;84:908–14.

45. Alonso-Castro AJ, Zapata-Bustos R, Dominguez F, et al. Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. Phytomedicine 2011;18:926–33.

46. Sun J, Fu X, Liu Y, et al. Hypoglycemic effect and mechanism of honokiol on type 2 diabetic mice. Drug Des Devel Ther 2015;9:6327–42.

47. Sun J, Wang Y, Fu X, et al. Magnolia officinalis extract contains potent inhibitors against PTP1B and attenuates hyperglycemia in db/db mice. Biomed Res Int 2015;2015:1–10.

48. Kim YJ, Choi MS, Cha BY, et al. Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat-fed mice. Mol Nutr Food Res 2013;57:1988–98.

49. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489–501.

50. Kim Y, Kang H, Jang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011;28:175–84.

51. Kang YJ, Park HJ, Chung HJ, et al. Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol Pharmacol 2012;82:1215–23.

52. Shen JL, Man KM, Huang PH, et al. Honokiol and magnolol as multifunctional therapeutic agents. Evid Based Complement Alternat Med 2010;2010:1–11.

53. Sarrica A, Kirika N, Romeo M, et al. Safety and toxicology of magnolol and honokiol. Planta Med 2018;84:1151–64.

54. Pyo MK, Lee Y, Yun-Choi HS. Anti-platelet activity of honokiol isolated from Magnolia officinalis. Planta Med 2002;68:513–15.